Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: Current status

Aman Chauhan, Susanne M. Arnold, Jill Kolesar, Hala Elnakat Thomas, Mark Evers, Lowell Anthony

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years. Methods: We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC. Results: Immune-checkpoint inhibitors might have clinical activity in LCNEC. Conclusion: Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.

Original languageEnglish
Pages (from-to)14738-14740
Number of pages3
JournalOncotarget
Volume9
Issue number18
DOIs
StatePublished - 2018

Bibliographical note

Publisher Copyright:
© Chauhan et al.

Keywords

  • High grade neuroendocrine carcinoma
  • Immune checkpoint inhibitors
  • Large cell neuroendocrine carcinoma

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: Current status'. Together they form a unique fingerprint.

Cite this